Ajinomoto Bio-Pharma Services

ABOUT AJINOMOTO BIO-PHARMA SERVICES

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization, with sites in Belgium, United States, Japan and India, providing comprehensive process development services, cGMP manufacturing and drug product fill finish services of small molecule and biologic APIs and intermediates. We offer a broad range of innovative platforms and capabilities to rapidly scale from clinical and pilot programs to commercial quantities, including: Corynex protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our clients’ needs.

Ajinomoto Bio-Pharma Services offers a range capabilities through its facilities around the world. Our facilities in Belgium, Japan, and India focus on conventional small molecule API and intermediate production. The focus at our California, USA facility is on large molecule and ADC manufacturing and aseptic fill finish services. Our Osaka, Japan facilities focus on oligonucleotide synthesis.

Our expertise and extensive knowledge of international requirements help assure your product will meet the highest possible quality standards. Our goal is to deliver quality product and personalized service, while providing flexibility and guidance to help our clients achieve their goals in a timely and efficient, cost-effective manner.

Ajinomoto Bio-Pharma Services is a member of the Ajinomoto Group companies, a global company focused on the research, development, and manufacture of high quality products for the pharmaceutical, specialty chemical, nutraceutical, sports nutrition, and health & beauty industries, as well as food seasonings and consumer food products.

VIDEOS AND WEBINARS

Aseptic Vial Filling

We offer a unique range of formulation and aseptic filling in vials, prefilled syringes or cartridges to address production needs that span from small early stage clinical products to larger scale commercial products.
High Potency Fill Line

Whether it's a liquid or lyophilized product, we provide capacity, quality, and expertise to ensure a stable supply of your promising therapeutics.
Aji Bio-Pharma and Catalisti

The HANU, a new photo-flow reactor, provides better process control, less risk in hazardous chemistry, less solvent use, and is better for the environment.
New High Speed Multi-Purpose Fill Line

Our fully contained and integrated OPTIMA line utilizes scan isolated barrier technology to ensure the required sterility for fill finish while offering flexibility to meet your cGMP, clinical, and commercial drug product manufacturing needs.
OPTIMA 7000 Fill Line

Ajinomoto Bio-Pharma Services is a leader in aseptic filling, offering a wide range of capabilities for vials with our OPTIMA 7000 fill line. The OPTIMA VFVM 7000 safely processes various types and classes of biopharmaceutical products in 2 mL to 100 mL sizes.
A Fill Finish Manufacturing Partner With Resources, Solutions, And Agility

We offer a unique range of formulation and aseptic filling in vials, prefilled syringes, or cartridges to address production needs that span from small early stage clinical products to larger scale commercial products.
Fully Integrated CDMO Services To Improve The Health Of Humankind

We provide therapeutic drug development and manufacturing services to biotechnology and pharmaceutical companies worldwide. We have the power to make your therapeutic vision a reality — from pre-clinical through commercial production.
Oligonucleotide Therapeutics: Bridging From Research To Commercial

Hideyuki Tanaka, Senior Director, Business Development, Ajinomoto Bio-Pharma Services, examines the necessary development and manufacturing expertise required to seamlessly transition from the research to commercial stages, to ensure the project runs smoothly from the early to late stage of development.
Plasmid Manufacturing For Gene Therapies: An Outsourcing Partnership

With an increased demand for plasmids for targeted gene therapeutic delivery, partnering with a CDMO equipped with the capacity, expertise and equipment for plasmid DNA production is critical to ensuring a stable therapeutic supply.
Are You Protecting Employees During HPAPI Manufacturing?

Tom Evans, MS, CMMS, an expert in hazardous manufacturing controls, discusses the planning, resources, and capabilities necessary to effectively produce a client’s highly potent active pharmaceutical ingredient (HPAPI) therapeutic, while effectively controlling the risk of exposure to operating personnel.